The Smartest Investors Club
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

The Smartest Investors Club

Investing

Zero Candida Technologies:Pioneering Technology-driven, Innovative Solution for Non-drug Treatment of Candidiasis

by December 18, 2024
December 18, 2024
Zero Candida Technologies:Pioneering Technology-driven, Innovative Solution for Non-drug Treatment of Candidiasis

Founded by a team of seasoned entrepreneurs and healthcare experts, Zero Candida (TSXV:ZCT) is a fem-tech pioneer, combining advanced artificial intelligence with non-drug diagnostics and personalized treatment modalities in a single device. The company developed an innovative, first-of-its-kind solution to the diagnosis and treatment of Candidiasis, a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva. The device offers precision therapy by eliminating fungal infections with over 99.99 percent effectiveness in just three hours, a revolutionary improvement over existing treatments.

Zero Candida is on track to complete clinical trials and file for FDA approval in 2024 with its innovative technology.

Zero Candida’s SMART vaginal diagnostic device utilizes blue light therapy to treat this widespread condition without drugs. This non-drug therapy addresses key issues associated with conventional antifungal medications, including reduced risk of drug resistance, minimized side effects, and potential for faster symptom relief

Company Highlights

Zero Candida Technologies is a fem-tech company focused on developing a SMART diagnostic and therapeutic device aimed at eliminating vaginal candidiasis (commonly known as yeast infection), a condition that affects three out four women globally.
Candidiasis a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva. In several cases, the current treatment for Candidiasis has been ineffective.
Zero Candida has completed proof-of-concept studies, and demonstrated near-complete fungal eradication with over 99.99 percent effectiveness in just three hours.
Founded by a team of experienced entrepreneurs and healthcare experts, the company is addressing the significant unmet needs of the women’s health market.
The fem-tech segment of the med tech market is expected to grow at a CAGR of 18.2 percent and is estimated to reach nearly US$30 billion by 2032. North America dominated the global fem-tech market with a share of 52.91 percent in 2023.
The company has already patented this technology in South Africa, while additional filings for patent application in the US and EU are underway.

This Zero Candida profile is part of a paid investor education campaign.*

Click here to connect with Zero Candida (TSXV:CZT) to receive an Investor Presentation

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Can Trump force Hamas to free the hostages they’re holding?
next post
First Helium Provides Year End Corporate Update

You may also like

Taroom Trough Coals Flowed for First Time –...

NorthStar Gaming is First to Market with a...

Cannabis Round-Up: US DEA Proposes Rescheduling, Canada Ignores...

IBN Announces Latest Episode of The MiningNewsWire Podcast...

What are Prefeasibility and Feasibility Studies? (Updated 2023)

WGC: Gold Demand Hits Q3 Record as Western...

Is the World Running Out of Copper? (Updated...

Riverside Resources and Questcorp Mining Execute Definitive Option...

Bitcoin Well Announces Company Record of New Users...

SAGA Metals Updates On Rio Tinto’s Field Progress...

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • NorthStar Gaming Announces Receipt of Management Cease Trade Order

    • Department of Justice opens criminal investigation into NY AG Letitia James

    • Brunswick Exploration Announces Brokered Private Placement for Gross Proceeds of up to C$2.5 Million, with a Lead Order from a Strategic Investor

    • Drill Contract Awarded for Elizabeth Hill. Technical Visit Completed to Define Drill Targets

    • $2.6M Placement and SPP to fast-track China entry and sales

    Categories

    • Business (1,633)
    • Investing (4,790)
    • Politics (7,535)
    • World (6,124)
    • Terms & Conditions
    • Privacy Policy
    • About us

    Disclaimer: thesmartestinvestorsclub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 thesmartestinvestorsclub.com | All Rights Reserved


    Back To Top